Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
824 studies found for:    trastuzumab
Show Display Options
Rank Status Study
21 Completed A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: GRN163L in combination with trastuzumab
22 Completed
Has Results
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Extrahepatic Bile Duct;   Adenocarcinoma of the Gallbladder;   Malignant Neoplasm;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
23 Unknown  Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer
Condition: Breast Cancer
Intervention: Drug: carboplatin and paclitaxel and or without trastuzumab
24 Recruiting Pre Operative Trastuzumab in Operable Breast Cancer
Conditions: Carcinoma Breast Stage I;   HER2 Positive Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Placebo
25 Not yet recruiting Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Condition: Gastric Cancer
Intervention: Drug: Trastuzumab + NK cells
26 Not yet recruiting Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: Trastuzumab Emtansine
27 Completed Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Condition: Solid Tumors
Intervention: Radiation: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
28 Active, not recruiting Dasatinib In Combination With Trastuzumab And Paclitaxel In The First Line Treatment Of Her2-Positive Metastatic Breast Cancer (MBC) Patients
Condition: Breast Cancer
Intervention: Drug: dasatinib plus trastuzumab plus paclitaxel
29 Completed Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Conditions: Breast Neoplasms;   Peritoneal Neoplasms;   Ovarian Neoplasms;   Pancreatic Neoplasms;   Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab;   Biological: trastuzumab
30 Recruiting Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
Condition: Posterior Fossa Ependymoma (PFEPN)
Interventions: Drug: Trastuzumab after SubQ GM-CSF;   Drug: Trastuzumab in combination with SubQ GM-CSF
31 Unknown  Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab or Lapatinib
32 Active, not recruiting A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Trastuzumab Emtansine
33 Terminated Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Intervention: Drug: Trastuzumab (Herceptin)
34 Active, not recruiting
Has Results
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Bevacizumab;   Drug: Docetaxel
35 Active, not recruiting Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Intervention: Drug: Trastuzumab
36 Active, not recruiting A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
Condition: Breast Cancer
Intervention: Drug: Trastuzumab
37 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
38 Recruiting NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
Conditions: Breast Cancer;   Gastric Cancer
Intervention: Drug: Trastuzumab + NK cells
39 Completed Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
40 Completed TBP Study With Capecitabine Plus Minus Trastuzumab
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Trastuzumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.